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Abstract
Alcohol use disorder is one of the most prevalent mental health disorders
worldwide, treatment options are limited, and relapse rates are high. There remains an
urgent need for effective treatments. Research involving the therapeutic potential of
classic hallucinogens has reemerged in recent decades and the hallucinogen psilocybin
has shown some promise in early studies. We aim to assess the efficacy of psilocybin in
treating alcohol use disorder with a 10-week double blind randomized double
dummy crossover control trial comparing psilocybin-assisted psychotherapy to
ketamine-assisted psychotherapy in individuals with alcohol use disorder. Our
primary outcome will be the mean percent heavy drinking days in the four-week periods
following drug administration sessions among participants in both treatment groups. We
hope that our results will provide further evidence for the therapeutic role of psilocybin in
addiction and that our study design may serve as a model for future randomized
controlled trials of psychedelics.
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Chapter 1 – Introduction
1.1 Background Information and Rationale
Alcohol use disorder (AUD) is one of the most prevalent mental health disorders
worldwide and the third leading preventable cause of death in the United States.1 The
National Institute on Alcohol Abuse and Alcoholism (NIAAA) defines AUD as a chronic
relapsing brain disease characterized by an impaired ability to stop or control alcohol use
despite adverse social, occupational, or health consequences.2 In the Diagnostic and
Statistical Manual of Mental Disorders, 5th edition (DSM-V), AUD comprises both
alcohol abuse and alcohol dependence disorders; it is further subclassified into mild,
moderate, or severe.3
AUD exacts a heavy social, economic, and medical burden in the United States
and globally. The World Health Organization (WHO) estimates that in 2012 the 12month and lifetime prevalence of AUD ranged from 13.9 to 29.1% of the global
population.4 In the U.S., an estimated 16 million people had AUD in 2015.5 AUD is a
significant contributor to global morbidity and mortality. In 2012, an estimated 3.3
million deaths, or 5.9% of all global deaths, were attributable to alcohol consumption.
The WHO ranks alcohol use as the eighth leading risk factor for death worldwide; in the
U.S., alcohol misuse is the third leading cause of death. AUD also has severe negative
effects on one’s productivity, interpersonal and psychological functioning, as well as
one’s short- and long-term health.4 Chronic excessive alcohol use can damage every
organ in the body and contributes to over 200 diseases and injury-related health
conditions, including liver cirrhosis, cancers, and dementia.1 These consequences come at
an economic cost including lost productivity and increased health care dollars. In 2006, it
is estimated that the economic cost of excessive drinking in the U.S. was $223.5 billion6.
1

Despite a high societal cost of AUD, treatment options are few and relapse rates
are high, even when treatment methods are combined.7,8 Common treatment options for
AUD are pharmacological interventions, behavioral therapy, and mutual support groups.
The FDA has approved only three drugs for AUD: Naltrexone, Acamprosate, and
Disulfiram, and these medications display poor efficacy, low adherence rates, or adverse
effects at a population level.5 Empirically-validated behavioral interventions include
cognitive behavioral therapy, motivational interviewing, and marital and family
counseling. Mutual support treatment groups include Alcoholics Anonymous and other
12-step programs. Due in part to the low efficacy rates of available treatments (and other
factors such as the stigma attached to this disease), the majority of people with AUD in
the U.S. go untreated. According to the NIAAA, based on data from 2001-2002, only
14.6% of people with AUD ever receive treatment.9 There remains substantial room for
the development of effective treatment alternatives and classic hallucinogens, particularly
psilocybin, have shown promise in early studies.
Classic hallucinogens exert their primary effects through agonist activity at
serotonin 2A (5-HT2A) receptors, and include lysergic acid diethylamide (LSD),
dimethyltryptamine (DMT), psilocybin, and mescaline. 10-12 These hallucinogens have
significant perceptual, cognitive, affective, and somatosensory changes, such as visual
and auditory hallucinations, difficulty thinking, mood disturbances and dissociative
phenomena.13 Interest in the therapeutic use of classic hallucinogens to treat addiction
and other mental health diseases originated in the 1950s, shortly after Albert Hoffman
discovered the psychoactive effects of LSD and recognized its therapeutic potential.14
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Over the subsequent 20 years until their scheduling by the US government as controlled
substances, psychedelic research expanded rapidly.
The earliest investigations began with Humphry Osmond and Abram Hoffer’s
work in Saskatchewan in the early 1950s, which emerged from clinical observations
suggesting that some alcohol dependent patients who had experienced delirium tremens
(a severe form of alcohol withdrawal that involves sudden and severe mental or nervous
system changes) subsequently decreased their drinking.15 They hypothesized that this
hallucinatory state was therapeutic and, therefore, LSD might reduce drinking by
inducing a delirium tremens-like state. At the conclusion of their work Osmund and
Hoffer ended up parting from their original hypothesis instead proposing that the
observed efficacy of LSD in their subjects was attributed to the drug’s ability to induce
deep introspection and insight, which made subjects more amenable to
psychotherapy.14,16,17
This led to numerous hypothesis-generating studies exploring the ideas put forth
by Humphry and Osmund. Researchers observed that relatively high doses of
psychedelics induce a “peak-psychedelic” or mystical experience of ego loss
(characterized by profound alterations in perception, mood, volition, cognition, and selfexperience), which impacts long-term behavior, personality and cognition.18,19
Furthermore, researchers found that when combined with psychotherapy, hallucinogens
facilitated the psychotherapeutic process and strengthened the therapeutic
relationship.14,20 Several studies on alcohol dependence found improvements in selfacceptance and interpersonal relationships, as well as reductions in craving and alcohol
use, among subjects treated with LSD.18,21,22
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1.2 Problem Statement
While the work done during the 1950s to early 1970s generated substantial
support for the therapeutic role of psychedelics in addiction, much of the research done
during that time period had significant methodological limitations; most notably, a lack
of randomized, double-blind, placebo-controlled trials.16,18 Further, the randomized
clinical trials that did exist did not preserve the blind (i.e. the hallucinogen under
investigation was compared to an inactive substance or a non-hallucinogen such as
amphetamine). Thus, the patients in the studies always knew when they were getting
hallucinogen or the presumed inactive comparator. When psychedelic research resumed
in the 1990s, researchers expanded upon the earlier work of their colleagues, refining
treatment models of psychedelic therapy and establishing specific guidelines for the
adequate study of treatment effectiveness of psychedelics.16,23 By the beginning of the
21st century, psychedelic research was again undergoing rapid growth.
In this new era of psychedelic research, major advances have been made towards
understanding the acute effects of psychedelics on physiology, cognition, emotion, and
brain function.24 Numerous studies have demonstrated the safety of these drugs when
administered in a controlled clinical setting. 24-26 Recent addiction research has shifted its
focus from LSD to psilocybin as a potential adjunct for treatment because psilocybin
works through the same mechanism of action, but is shorter-acting and overall, better
tolerated.27 Several lines of evidence suggest that psilocybin has clinically relevant
effects in the treatment of addiction. Recently completed proof-of-concept studies of
psilocybin in conjunction with psychotherapy for nicotine and alcohol dependence
demonstrated that the intervention led to substantial decreases in use of the target
substance28,29 This proof-of-concept study of psilocybin for AUD was the first to ever test
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this relationship28. Currently, Phase 2 randomized-controlled trials (RCTs) are underway
to test the efficacy of psilocybin-assisted treatment of tobacco, alcohol, and cocaine use
disorders. Given the current plethora of evidence in support of psilocybin as a useful
pharmacological tool for treatment of AUD and the dearth of RCTs investigating this
hypothesis, further investigation is warranted.
1.3 Goal and Objectives
This study aims to further clarify whether psychedelic-assisted treatment with
psilocybin of AUD is clinically useful. Specifically, this study aims to: (1) characterize
the acute effects of psilocybin in alcoholic patients (2) evaluate the effect of psilocybin
treatment on drinking outcomes relative to a ketamine control.
1.4 Hypothesis
Psilocybin administered in conjunction with targeted psychotherapy will lead to a
greater clinically significant reduction in the mean percent heavy drinking days compared
to active placebo ketamine among individuals with alcohol use disorder.
1.5 Definitions
Mean percent heavy drinking days: mean days during which participants consume five or
more standard drinks (14 g of alcohol per drink) if male, or four or more standard drinks
if female.
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Chapter 2 – Review of the Literature
2.1 Introduction – Literature Search Criteria
A thorough review of the literature was conducted from December, 2018 to April,
2019 using Ovid (Medline), PubMed, Embase, and Cochrane Medical Library using a
concept table (Appendix A). Searches included clinical trials, randomized control trials,
systematic reviews, and meta-analyses. All publications that used hallucinogens as a
therapy for addiction were selected for further review. Additional publications relevant to
this study were obtained through forward searches and hand searches, and included in the
review.
2.2 Overview of Current Treatments for AUD
AUD is a heterogenous disease with a wide range of phenotypes, and individual
response to treatments varies greatly. Accordingly, current interventions for AUD
integrate pharmacological treatment with psychosocial therapy to target the genetic,
psychological and environmental factors that are believed to interact to cause this
disorder. Goals of treatment include: achieving abstinence; reducing the frequency and
severity of relapse, and improving both health and psychosocial functioning.
2.2.1 Approved Medications for AUD
Disulfiram was the first medication to become approved by the FDA for the
treatment of AUD. It is prescribed as an anti-craving medication to abstinent individuals
with a high motivation to stay sober, since it works by inhibiting the metabolism of
alcohol which induces severe adverse reactions if alcohol is ingested. While disulfiram
has been found to act as a deterrent to alcohol ingestion in a controlled environment, its
efficacy drops significantly in an unsupervised environment.1 As a result, in “real world”
RCTs, adherence rates were low and disulfiram did not show efficacy.2 A meta-analysis
8

of open-label trials and RCTs of disulfiram use in alcoholics found that overall, compared
to controls, disulfiram showed a higher success rate, with Hedge’s g = 0.58 (95% CI =
0.35-0.82). However, only open-label trials showed significant superiority over controls
(g = 0.70, 95% CI = 0.46-0.93). Disulfiram was also found to be more effective than the
control condition when compared to naltrexone (g = 0.77, 95% CI = 0.52-1.02) and to
acamprosate (g = 0.76, 95% CI = 0.4-1.48)3. While the rate of disulfiram prescription
continues to climb in some parts of the world, overall disulfiram prescription rates are
dropping as its role in treatment is generally displaced by more recently introduced
medications.4
Naltrexone is a non-selective opiate antagonist that targets and blocks the
rewarding neurobiological effect of alcohol.1,5,6 It is prescribed as an adjunct to
psychosocial intervention for reducing heavy drinking in alcohol dependent individuals
and prolonging abstinence.1,7 Trajectory-based studies of naltrexone suggest that it is
most effective in patients who have a high likelihood of drinking heavily on a regular
basis during treatment and that it is ineffective in patients who drink sporadically during
treatment.8,9 A 2013 meta-analysis of RCTs of naltrexone for alcohol dependence found a
small but significant effect of Naltrexone compared to placebo on the outcome of heavy
drinking (g = 0.189, CI 0.123-0.255, p < 0.001).10
Acamprosate is an analogue of GABA and is thought to act as a functional
glutamate antagonist, dampening glutaminergic hyperactivity associated with alcohol
withdrawal.11,12 Results on the efficacy of Acamprosate are mixed. A meta-analysis of
RCTs comparing acamprosate to naltrexone for alcohol dependence found a small but
significant effect of Acamprosate compared to placebo on the outcome of heavy drinking

9

that was similar to that of Naltrexone (g = 0.359, CI 0.246-0.472, p < 0.001).10 However,
it did not show efficacy on its primary endpoints in either of the large RCTs conducted in
the U.S. including NIAAA Project COMBINE, the largest pharmacotherapy study in the
history of the field.13,14
2.2.2 Evidence-Based Psychosocial Interventions
Psychosocial interventions are psychologically-based interventions that aim to
reduce consumption behavior or alcohol-related problems.15 The most commonly used
interventions are motivational interviewing (MI), cognitive-behavioral therapy (CBT),
brief interventions, and Twelve-step facilitation programs (TSF).16 Clinical trials have
found no superiority of one behavioral treatment over another.1 These interventions have
shown moderate efficacy in reducing drinking and maintaining abstinence, and not all
individuals benefit from psychosocial therapy.
The psychosocial intervention proposed in this study is motivational enhancement
therapy (MET), which is a type of MI, and a common intervention for the treatment of
AUD; it is one of the few treatments designed specifically for abstinence initiation17.
MET consists of a patient-centered therapy that aims to produce rapid internallymotivated changes by exploring and resolving ambivalence towards behavior.18 A
systematic review of RCTs published between 1997 and 2007 assessing the beneficial or
detrimental effects of motivational techniques in the treatment of alcohol dependence
found that MET was significantly more effective than a minimal intervention control at
reducing heavy alcohol use when assessed at five-month follow-up (moderate effect
size).18 Additionally, MET was favored over control in individuals who drank
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excessively and frequently at six-month follow-up (large effect size). The analyses
showed a trend favoring MI with relapse prevention over control (p = 0.07).18
2.3 Promise of Psilocybin-Assisted Psychotherapy for AUD
2.3.1 Clinical Studies of Classic Hallucinogens in Substance Use Disorders
The main focus of research during the 1950s-1970s in the field of addiction was
the use of LSD for the treatment of alcoholism. Following the success of Drs. Hoffer and
Osmond, administration of LSD with psychotherapy to alcoholic patients became an
accepted clinical treatment in Saskatchewan and the subject of many studies. The
majority of these studies had significant methodological flaws, including an absence of
adequate control groups; substantial variation in dose quantity and duration; a lack of
control for confounding factors; non-standardized criteria for therapeutic outcome; and
diverse theoretical approaches for assessing beneficial effects.19,20 In a recent metaanalysis of these studies, about a dozen were reported to have some form of control
group, only six were randomized trials (N = 536), and of these, five were fully doubleblind.21 All of these studies employed a single high-dose LSD session and controls that
included inactive placebo, low-dose LSD (50 mcg), ephedrine, and amphetamine. At the
post-treatment follow-up (which ranged from one to 12 months), the odds ratio for
improvement was 1.96 (95% confidence interval [1.36-2.84], Z = 3.59, p = 0.0003).
Among the five studies reporting dichotomous outcomes, 59% of the LSD-treated
participants were significantly improved vs. 38% of the control participants (pooled
benefit difference 16%, 95% confidence interval 8%-25%, p = 0.0003, number needed to
treat = 6). All six studies demonstrated robust treatment effects, which remained
significant at six months follow-up.19,21 Despite their methodological flaws, these studies

11

provide persuasive preliminary evidence for the efficacy of 5-HT2A receptor agonists in
the treatment of alcoholism.
Clinical research on psilocybin for the treatment of addictions is still in its early
stages. To date, there are only two completed studies to explore the efficacy of
psilocybin-assisted treatment for substance use disorders.22,23 The first study, led by
Matthew Johnson at Johns Hopkins University, was an open-label, dose-escalating study
to determine the safety and feasibility of oral psilocybin as an adjunct to tobacco smoking
cessation treatment in 15 tobacco-dependent adults23. Oral psilocybin was administered
in a moderate (20 mg/70 kg) and then high (30 mg/70 kg) dose during two treatment
sessions at five and seven weeks, with an optional third session at week 13. Prior to the
first psilocybin administration, subjects attended four sessions of manualized intervention
consisting of CBT for smoking cessation and preparation for the drug sessions. Results
demonstrated substantial decreases in nicotine use among subjects. At the six-month
follow up, 80% of subjects (12/15) showed seven-day point prevalence abstinence (p =
0.001), and 73% (11/15) were biologically confirmed to have quit smoking. This
abstinence rate greatly exceeds rates commonly reported for other behavioral and/or
pharmacological smoking cessation therapies, which are typically less than 35%.23
Importantly, no significant treatment-related adverse effects were found.
The second study, led by Michael Bogenschutz, investigated the efficacy of
psilocybin-assisted psychotherapy with MET in 10 alcohol dependent individuals.24
Participants received orally administered psilocybin (0.3 mg/kg and 0.4 mg/kg) in one or
two supervised sessions at four and eight weeks, with an optional dose increase at week
eight along with nine total MET sessions. This study found a significant increase in
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abstinence among subjects following psilocybin administration (p < 0.05) with gains
largely maintained at follow-up to 36 weeks. Furthermore, the intensity of effects in the
first psilocybin session was found to be a strong predictor of change in drinking during
weeks five to eight (r = 0.76 to r = 0.89). No significant treatment-related adverse effects
were found.
2.3.2 Clinical studies of Psilocybin in Other Psychiatric Diseases
Preceding the research on psilocybin as a potential treatment for addiction,
psilocybin was investigated during the 1950s to 1970s by researchers seeking to
characterize its pharmacological and safety profile, as well as its potential therapeutic
properties. Research demonstrated that psilocybin, similar to LSD, reliably induces
profound changes in sensory perception, emotion, thought, and sense of self,
characterized by marked alterations in all mental functions.25 As a result, some therapists
incorporated psilocybin into their psychotherapy sessions in order to facilitate access to
subconscious conflicts and memories and found that it led to the successful treatment of
many previously therapy-resistant patients.26
In the modern era of psychedelic research, more rigorous studies have been
conducted to investigate the psilocybin’s therapeutic potential in a variety of mental
health disorders. For example, in 2006, a dose-escalating proof-of-concept study was
conducted to test the effects of varying doses of psilocybin on symptoms of obsessivecompulsive disorder (OCD)27. The study included nine adults with symptomatic OCD
who received doses of psilocybin ranging from very low (25 g/kg) to very high (300
g/kg). Dosing escalation occurred sequentially, at least one week apart. Results found
that all doses produced significant decreases in OCD symptomatology (measured via the
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Yale-Brown Obsessive-Compulsive Scale, YBOCS) during one or more of the testing
sessions. Investigators concluded that psilocybin was associated with acute reductions in
core OCD symptoms in this population.27,28
Another dose-escalating study investigated safety and efficacy outcomes for up to
six months in 20 adults with moderate to severe treatment resistant depression.29 Oral
psilocybin was administered at a low dose (1 x 10 mg) followed by a high dose (1 x 25
mg) one week later. Results revealed a significant decrease in self-reported depression
scores in all participants relative to baseline, which lasted up to the last follow-up at six
months (Cohen’s d = 2.2 at week 1 and 2.3 at week 5; both p < 0.001). Additionally, four
participants met the criteria for remission at the five-week time point through the last
follow-up at six months (Cohen’s d = 1.4, p < 0.001).28,29
Other psilocybin research has focused on evaluating its efficacy in treating
anxiety and depressive symptoms related to advanced-stage cancer diagnoses.30-32 In a
2011 randomized, double-blind, placebo-controlled crossover study, 12 adults with
advanced-stage cancer and reactive anxiety were treated with either 0.2 mg/kg of oral
psilocybin or oral placebo (niacin, 250 mg) in a randomized order.30 Anxiety and
depression outcomes revealed an overall decrease in scores compared to niacin placebo
by almost 30% from the first treatment session to one month after the second session (t11
= -2.17, p = 0.05); this difference was sustained and became significant at the six-month
follow-up point (t7 = 2.71, p = 0.03). Authors observed that psilocybin produced moodelevating effects that persisted after the acute effects of the drugs, facilitated therapeutic
bonds, and ameliorated underlying psychological demoralization.
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A notable limitation of this study is that a relatively low dose of psilocybin (0.2
mg/kg) was chosen for the experimental condition. This could have accounted for the
modest effects found for psilocybin on anxiety and depression outcomes. Similar studies
conducted in the 1960s and 1970s, which utilized much higher doses of hallucinogens,
reported that subjects experienced profound psychospiritual epiphanies, which correlated
with therapeutic outcome. These results are consistent with other recent studies that have
demonstrated an association between higher doses of hallucinogens and transcendent
states of consciousness.31,33,34
Two subsequent RCTs that investigated the effects of psilocybin in this
population. The first investigated the effects of psilocybin doses (high vs. low) on
anxiety- or depressive-related outcomes in 56 adults with cancer.31 This study used a
double-blind crossover design to randomize subjects (N = 56) to one of two sequences
involving a low dose (“placebo-like”) or high dose of oral psilocybin. Primary outcome
measures of depression and anxiety demonstrated sustained and statistically significant
improvements following high-dose psilocybin treatment vs. placebo for up to six months.
The second study, which investigated the efficacy of a single dose of psilocybin
vs. placebo in conjunction with psychotherapy in 29 individuals, found similar results.32
In this crossover study, 29 subjects were given a single dose of 0.3 mg/kg psilocybin or
250 mg niacin, both in conjunction with psychotherapy, with crossover occurring at
seven weeks. Results found that the group that received psilocybin first showed
“immediate, substantial, and sustained” clinical improvements in anxiety and depression
scores, which lasted through the seven-week time period between treatments and up to
the six-month follow-up. The group that received niacin first showed transient reductions
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that were not sustained at seven weeks. After these subjects received psilocybin,
immediate and sustained reductions in anxiety and depression were observed 35. In all,
approximately 60-80% of the 29 total patients, experienced enduring and clinically
significant reductions in depression or anxiety at the six-month follow-up32.
Taken together, these studies demonstrate the safety and feasibility of psilocybinassisted treatment when administered in a controlled clinical setting to individuals with
varying mental health disorders. Furthermore, they lend substantial support for the
efficacy of psilocybin in these populations.
2.3.3 Safety Considerations for Psilocybin Administration
Additional clinical studies on psilocybin in healthy volunteers further support the
feasibility and safety of psilocybin-assisted psychotherapy.19,24,27,31,32,34,36,37 Studies on
the psychopharmacological properties of psilocybin have found that when psilocybin is
ingested by humans it is rapidly enzymatically cleaved to produce psilocin, which exerts
its primary psychoactive effects at serotonin 5-HT2A/C receptor sites in the brain. The
bioavailability of oral psilocybin is approximately 50%, and the half-life of psilocin in
blood is two to three hours. Psychoactive effects become noticeable within one hour of
administration, peak around two hours, and disappear around six hours.28,38 Accordingly,
protocols for clinical trials have mandated that subjects be observed until about eight
hours after psilocybin dosing.
A meta-analysis of eight double-blind placebo-controlled studies of 110 healthy
volunteers who had received oral psilocybin ranging from 45-315 g/kg in one to four
sessions, demonstrated that the psychomimetic and physiologic effects of psilocybin are
dose-dependent.28,36,39,40 Common symptoms included profound changes in mood,
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perception, thought, and self-experience. Importantly, most subjects described the
experience as pleasurable, enriching, and non-threatening. Factors other than dose have
also been reported to modulate psilocybin’s overall effects, such as personality structure
and setting (i.e. environment). See Section 2.4.1 for more on the effects of set and setting.
The most commonly reported adverse psychological events of psilocybin were
anxiety, negative emotional states, and paranoid/delusional thinking, and the most
commonly reported physical effects were increased blood pressure, heart rate, and mild
nausea and headache.28 In order to maximize safety in clinical trials with psilocybin, a
structured and supportive intervention protocol has been established for researchers to
follow.28,41
Based on the available literature, researchers have not found evidence of addictive
properties of psilocybin. Previous clinical studies with individuals with no or minimal
(less than 10 lifetimes uses and no use within the last five years) history of hallucinogen
use, who were given psilocybin in the context of a supervised and controlled research
setting, concluded that, on follow-up, there were no incidents of illicit hallucinogens
abuse in these subjects. Additionally, a retrospective analysis of the acute, short- and
long-term subjective effects of psilocybin in healthy humans collected from previously
conducted double-blind, placebo-controlled trials, revealed that the majority of
participants reported “no change” in their psilocybin use following study drug sessions,
as well as “no change” in their overall drug consumption habits (i.e. use of alcohol,
nicotine, cannabis, MDMA). Those who did report changes often described decreased
consumption after psilocybin28,39. Based on this evidence, it is not expected that the
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hallucinogen-naïve participants in this study will develop dependence after psilocybin
exposure.
2.3.4 Safety Considerations for Ketamine Administration
Ketamine is a dissociative anesthetic that is widely and safely used intravenously
(IV) and orally in a clinical setting as a short-term anesthetic in doses ranging from 1-2
mg/kg administered IV, or 4-11 mg/kg administered intramuscularly. (Note: dissociative
anesthesia is a form of anesthesia that lacks complete unconsciousness but is
characterized by catatonia, catalepsy, and amnesia).42 Ketamine is classified as an
“atypical hallucinogen” due to its psychoactive properties. At certain doses it produces
dissociative and psychomimetic effects similar to those of classic hallucinogens,
including enhanced sensory perception, emotional connectedness, feeling of unreality,
visual hallucinations, and altered perceptions of self and time.43 Unlike classic
hallucinogens, which are primarily mediated by agonist action at 5-HT2A receptors,
ketamine is a moderate affinity non-competitive N-methyl-D-aspartate (NMDA) receptor
antagonist.44
Ketamine’s psychopharmacological effects are dose- and concentrationdependent.45 Lower doses (i.e. 0.1 mg/kg administered IV over 40 minutes) induce a mild
state of euphoria that is similar to that produced by a glass of wine, whereas higher
subanesthetic doses (i.e. 0.5 mg/kg, IV over 40 minutes) produce alterations in sensory
perception, feelings of unreality, and in some subjects mild psychosis.42,43,45 Ketamine
has been found to unfavorably affect cognition (i.e. decrease mental sharpness, recall, and
recognition, as well as explicit and implicit memory) either during or shortly following
administration.43 During ketamine infusion, it is common for the perceptual effects to be
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accompanied by anxiety. At doses where it alters perception, it also produces nystagmus
and this symptom is associated with nausea and, in some cases, vomiting. In patients who
are sensitive to ketamine-induced nausea, this symptom may be managed by pretreatment
with odansetron, which does not seem to alter its therapeutic or psychological effects
(Robert Ostroff, personal communication). In healthy subjects, ketamine typically
produces a mild elevation in blood pressure and pulse rate that typically does not require
medical intervention. Repeated ketamine administration appears to be safe when
managed clinically. However, long-term heavy recreational use of ketamine, which can
reach daily levels of 100-times the therapeutic dose, may lead to flashbacks, attentional,
and other cognitive dysfunctions.42,43,46-48
Ketamine has proven to be a desirable drug due to its short half-life and lack of
clinically significant severe adverse effects. In addition to its anesthetic action, it also
possesses analgesic effects, anti-inflammatory effects, and antidepressant activity.
Repeated subanesthetic ketamine has been shown to improve clinical outcomes for
treatment resistant depression.49-51
2.4 Review of Relevant Methodology
2.4.1 Study Design and Possible Confounders
The unique challenges of conducting experimental research with psychedelics has
been discussed extensively throughout the literature.19,52-56 These challenges stem from
the unique properties of psychedelic drugs and include design issues relating to subject
selection, the difficulty of blinding to the subjective effects of the drug, and the
possibility of complex interactions between psychological and environmental factors
prior to, during, and after drug administration.
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Prior hallucinogen experience
With regards to the selection of experimental subjects, an important consideration
is a subject’s prior hallucinogen experience. Previous studies have used varying selection
criteria for hallucinogen experience. For example, the open-label study with psilocybin
for AUD treatment required that individuals have no hallucinogen use in the previous 30
days, and lifetime use not exceeding 10 occasions.24 In contrast, the open-label trial on
nicotine dependence required all subjects to have had at least one prior and well-tolerated
occasion of hallucinogen exposure.23
In this proposed study, we believe it will be important to enroll only hallucinogennaïve participants so that they will not be able to recognize or differentiate between the
psychedelic drug effects of psilocybin and ketamine due to a lack of previous experience.
This will help to maintain the blind. This is particularly important in a trial with
psychedelics because these drugs have been shown to be particularly susceptible to
expectancy bias – that is, the individual’s state of mind and expectations when taking the
drug strongly influence the nature of the drug experience. Thus, minimizing expectancy
bias enables us to better control the quality of the psychedelic experience. This selection
criteria will also enable use to avoid selection bias, where individuals who have
previously had positive experiences with hallucinogens may be more likely to participate.
Maintaining the double-blind
Maintaining the double-blind in studies with psychedelics is considerably difficult
due to the pronounced acute subjective and objective effects of these drugs, which
provide subjects and investigators with ample clues for identifying the experimental
condition. To a certain degree, this problem is shared by other psychoactive drugs (i.e.
stimulants, sedatives, and opioids) that produce discriminable effects, and typically, the
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solution is to use an active placebo in lieu of an inert placebo. However, in trials with
psychedelics, even active placebo has been easily distinguished from the experimental
condition by participants and investigators.29
Previous psilocybin trials have used active controls such as niacin, ephedrine, and
methylphenidate, due to their ability to induce some of the same mild physiological
symptoms as psilocybin (i.e. sense of warmth, arousal, tingling sensation, and flushing,
nervousness, and/or increased positive mood) without altering the subject’s psychological
state.30,32 However, as Grob and his team discovered in their trial assessing the efficacy of
psilocybin vs. niacin placebo in advanced stage cancer patients, “the drug order was
almost always apparent to subjects and investigators whether the treatment was
psilocybin or placebo.” Similarly, Ross and his team concluded that staff guessed
correctly 97% of the time whether the participant was administered psilocybin or niacin
placebo rendering blinding completely unsuccessful. In fact, it is estimated that in RCTs
with LSD or psilocybin, session monitors (therapists present during the drug sessions)
were able to accurately discriminate between these experimental drugs and active
placebos in 77-95% of the time.55
In other trials, very low (“placebo-like”) doses of psilocybin have been used with
the intention of providing noticeable psychoactive effects without the therapeutic effect
of higher doses. In the psilocybin trial for OCD, a very low dose (25 g/kg) psilocybin
placebo was concluded to be an ineffective blind: “subjects experienced stronger than
anticipated response to this dose, and its clinical effects were also greater than
anticipated. This response to VLD impedes the use of VLD as a placebo comparator.”27
Another trial that used a very low dose of psilocybin as a placebo, had somewhat more
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success in maintaining blinding, stating that “blinding procedures provided some
protection against a priori monitor expectancy strongly determining outcomes of the
psilocybin dose manipulation.”
A limitation to a low-dose psilocybin placebo is that it is difficult to exclude the
possibility that even a low-dose psilocybin placebo control may have some
psychomimetic properties and partially contribute to treatment effects (as mentioned
earlier). “A wiser choice,” one investigator advises, “may be a control that has a different
mechanism of action yet is still capable of producing similar psychoactive symptoms so
that participants may remain blinded to their condition/treatment.”30 Heeding this advice,
we have selected ketamine as the control condition in our study, since it closely mimics
psilocybin’s psychoactive effects, while still possessing a radically different mechanism
of action from psilocybin.57
This design will be in contrast to Bogenschutz’ current study on psilocybin for
AUD, which is using diphenhydramine (50 mg) as an active control. (Diphenhydramine
at this dose has a side effect profile that includes pupil dilation, facial flushing,
hallucinations, and ataxic gait, which overlap with some of the physiologic side effects of
psilocybin). We believe that blinding will be significantly compromised in this RCT.
Set and Setting
An individual’s state of mind and expectations when taking a psychedelic, as well
as the context (i.e. physical and interpersonal environment) in which the individual takes
the drug significantly contribute to the overall quality of the drug experience.
Consequently, the effects of hallucinogens can vary markedly from individual to
individual and from session to session. This idea was introduced early on in psychedelic
research, and dubbed “set and setting.”55,58,59 The elements of “set and setting” are
22

essential to account for within the design of a clinical trial on psychedelics because the
overall quality of the drug experience is believed to mediate the persisting therapeutic
effects of the drug.
Research to support this idea includes the finding that “pre-session negative mood
consisting of anxiety or depression has been shown to significantly predict anxious or
other negative experiences during the session.”41 In addition, work by Griffiths and his
team with psilocybin in healthy individuals found that the presence/absence, and quality
of the mystical experience during the drug’s acute effects were significant predictors of
beneficial change in volunteers. While research to systematically evaluate how specific
elements such as set and setting may impact therapeutic outcomes is lacking, this idea is
still generally accepted by psychedelic researchers.
Accordingly, Johnson and colleagues have published a set of guidelines for
researchers to follow in order to control for the variables discussed here, maximize
therapeutic potential, and ensure patient safety. These guidelines are based on previous
research and are closely followed by researchers in this field. In addition to these
guidelines, clinically validated instruments have been developed to qualify the
dimensions of the drug experience and its overall intensity. All of the methods relevant to
this proposal will be incorporated into our design (see Section 3.6.2).
Crossover Design
Taking into consideration the various challenges of RCTs with psychedelics, as
well as our study’s objectives, we selected a crossover design. Crossover designs have
been used extensively in early-phase trials, including in studies with psilocybin in normal
volunteers and individuals with anxiety and depressive disorders19,30-32. The most
common type of crossover design consists of a two-period, two-treatment design wherein
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subjects are randomly assigned to receive either treatment A and then B, or B and then A.
A crossover design is ideal for studying treatment of chronic conditions in which clinical
status is unlikely to change without treatment. It is also best for studying treatments that
have rapidly evident effects.60,61 A strength of this design is that it reduces betweenpatient variation, since subjects act as their own controls. Additionally, since all subjects
receive the experimental treatment, the issue of excluding some individuals from a
potentially beneficial treatment does not exist.
A limitation of the crossover design is the potential for carryover effects.
Carryover occurs when the effect(s) of the treatment administered in the first period
carryover into the second treatment period. In order to prevent carryover effects, we will
include a four-week active washout period between treatments A and B (during which
only MET will be administered). Based on previous research on the time course of acute
effects of ketamine and psilocybin, we believe this length of washout is sufficient.3032,43,49,62

Another limitation is the possibility of a period effect, which occurs when the

order in which the two treatments are administered affects the outcome. We will account
for these limitations in our statistical analysis by running a between-group analysis to test
the effect of the active intervention, and a within group analysis to test the effect of order.
2.4.2 Primary and Secondary Outcomes
There are no generally accepted criteria for success in addiction treatment
research.19 In AUD research, there is a consensus to include alcohol consumption as a
measure of treatment outcome, however, researchers debate over how to operationalize
alcohol consumption. The FDA accepts complete abstinence and no HDD as clinical trial
endpoints.5 Dimensional measures that include abstinence are, time to first drink, time to
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relapse, and longest duration of abstinence. Although long-term total abstinence is the
most desirable outcome, recent evidence suggests that these endpoints may be overly
strict and may not capture all individuals who respond to a medication. As the authors of
Project MATCH point out, alcohol abusers demonstrate improved outcomes over time,
therefore, a dichotomous measurement of abstinence or drinking is not sensitive to
improvement.63,64
Other dimensional measures that have been proposed include percent days
abstinent, percent heavy drinking days, and drinks per drinking day. The Alcohol Clinical
Trials Initiative (ACTIVE) workgroup and affiliated researchers have advocated for such
alternate endpoints, arguing that individuals who are able to reduce their alcohol
consumption to low-risk levels during treatment do not substantially differ from
abstainers in terms of healthcare utilization or medical costs and they are able to sustain
this reduction in alcohol consumption over several years.5
In 2001, an NIAAA panel designated PHDD as the optimal outcome measure for
future alcohol treatment efficacy trials because it can capture both abstinence and
improvement over time.63 Accordingly, many recent large-scale trials have used these
alternative endpoints.11,13,63-70 In keeping with the NIAAA recommendations and the
trends of recent trials (including Bogenschutz’s studies on psilocybin for AUD), this
outcome measure is the most logical choice for this study; it will enhance validity by
allowing for consistency in evaluation and cross-study comparisons.
In order to capture this data, the timeline follow-back (TFLB) instrument will be
used. The TFLB is a daily drinking estimation method that been validated by the
American Psychiatric Association and the NIAAA.71 The NIAAA recommends it as the
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measure of choice when drinking is variable or when relatively precise estimates of
drinking are needed (i.e. frequency of drinking at specific levels). An alternative means
of assessing DDE is through Form 90, however, TFLB has been determined the most
psychometrically sound and widely used DDE method.63 An important advantage of this
method is that researchers are able to reanalyze the raw data to generate alternative
drinking outcomes of interest not assessed in a study (i.e. percent days abstinent, days to
first drinking day, number of days to first drink), which enhances reliability. Limitations
of this method include that it requires more resources such as interviewer and participant
time, training, and increased burden on the respondents, which could increase attrition
rates.
The non-drinking outcome measures in this study will be three well-established
mediators of addictive behavior – self-efficacy, craving and motivation – that have been
implicated as significant predictors of treatment outcome in alcohol addiction and that are
potentially modifiable through therapeutic use of classic hallucinogens.72 Self-efficacy is,
“the conviction that one can successfully execute behavior required to produce the
[desired] outcomes.”72 It provides a means to predict and understand psychological
changes that occur during treatment. Motivation can affect drinking by “[influencing]
patients to seek, complete, and comply with treatment and make successful long term
changes in drinking.”72 Hallucinogen treatment is theorized to enhance motivation
through several mechanisms. During acute intoxication, hallucinogens are known to
cause a subjective experience of mysticism and/or other novel psychological experiences
or insights. This in turn may increase one’s belief in the possibility of change (selfefficacy), heighten one’s awareness of negative consequences, and change one’s
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perspective in favor of a greater desire to change, which together may enhance one’s
motivation.72 MET may further facilitate this process by directly targeting motivation as
the main mechanism of behavioral change.
Craving is a multi-dimensional construct which includes motivational, affective
and cognitive components.72 Many studies have demonstrated a positive relationship
between craving intensity and relapse. While there are yet to be any clinical trials with
hallucinogens to investigate the role of alcohol or drug craving in treatment, Bogenschutz
recommends that future trials include assessment of craving to investigate this question.
He hypothesizes that, “stimulation and persistent activation of serotonergic pathways
could affect craving by diminishing attentional bias, normalizing stress response,
improving mood, or diminishing anxiety.72
Additional measures will be included to capture the quality of the participants’
acute hallucinogenic experience. This is an essential element of hallucinogenic trials
since a basic principle of the psychedelic treatment model holds that the quality of the
acute experience mediates long-term improvements in mental health.33 Indeed,
Bogenschutz and his team found this to be true in their pilot study on psilocybin for
alcoholism which demonstrated that both mystical experience and broader measures of
the intensity of subjective effects were associated with improvement in drinking.24 “The
patient’s conscious experience during the drug’s acute effects is essential for long-term
clinical benefit,” Bogenschutz explains.73 The assessments used in this study to capture
subjective experience of psilocybin will include the APZ Questionnaire (a version of the
Altered States of Consciousness Rating Scale, ASCRS), to be completed by the
participants, and a Monitor Session Rating Form (MSRF), to be completed by monitors
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present during the drug sessions. (The MSRF will expand upon the subjective reports of
the participants with monitor ratings of participants behavior and affect). The APZ is a
clinically validated measure, commonly used throughout psychedelic research. In
addition to capturing subjective data such as mood, perceptions, and cognitions, the APZ
Questionnaire will also enable a characterization of the intensity of the experience, and
inform researchers of possible safety considerations. By incorporating this wellestablished and commonly used measure into our study, the validity will be enhanced by
enabling comparisons between other trials.
An assessment of the presence or absence of the mystical experience as well as its
quality, is an important component of this study. The mystical experience will be
assessed by the Mystical Experience Questionnaire (MEQ-30). Numerous clinical trials
with psilocybin and other classic hallucinogens have attempted to evaluate the occurrence
and character of individual mystical experiences that hallucinogens have been found to
induce due to cumulative evidence over the years that it may serve as a valuable predictor
of positive outcomes.33,34,72,74-76
Dating back to 1950s, Drs. Hoffer and Osmond noticed an unexpected effect of
LSD in alcoholic patients: it seemed to induce an experience “so profound and
impressive that [one’s] life experience in the months and years to follow [would become]
a continuing growth process.” As other researchers at the time similarly noted, LSD
evoked a “transcendent, overwhelming, conversion-like experience” in patients and,
“clients who [made] successful recoveries often [attributed] their success to a spiritual
experience or enlightenment.” Bill Wilson (the founder of Alcoholics Anonymous)
credits the spiritual experiences he had while using LSD as the impetus for his sobriety.
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In his treatment model for Alcoholics Anonymous, he incorporates a similar concept,
which emphasizes the importance of an experience of spiritual insight in the path to
sobriety. 73 77 Other Twelve-Step programs are similarly based on the idea that spiritual
change can bring about recovery from addiction.72
Contemporary addiction research has examined the role of a spiritual experience
in recovery. One large study on alcoholism treatment found that subjects who reported a
recent spiritual awakening were found to have markedly increased rates of 12-month
continuous abstinence compared to those who did not report this experience (odds ratio =
3.9).78 In another study, 82% of individuals who reported a spiritual awakening between
baseline and follow-up reported abstinence compared to 55% of those not reporting such
an experience (55%) (X2 = 26.48, p < 0.001).72,79 Recent studies with psilocybin have
demonstrated that the self-reported “mystical” dimension experienced while taking
psilocybin significantly predicts the lasting personal significance of the experience.34,37
More research is needed to further investigate the role of the mystical experience in
alcohol treatment.
2.4.3 Inclusion and Exclusion Criteria
The inclusion and exclusion criteria for this study are based on established
guidelines for the safe administration of hallucinogens in human volunteers, as well as
Bogenschutz and his team’s pilot and RCT studies on psilocybin for AUD, and an
ongoing study by McAndrew and her team on ketamine-assisted-therapy for
AUD).24,41,80,81 In accordance with the guidelines, all participants will be in good general
health, as assessed by detailed medical history, physical examination, 12-lead ECG,
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blood chemistry profile, hematology, and urinalysis. Pregnant women or those not
practicing effective means of birth control will be excluded.
Due to the side effect of psilocybin and ketamine to moderately increase pulse
and both systolic and diastolic blood pressure, volunteers will be excluded if they have
uncontrolled hypertension (defined as a blood pressure exceeding 165 systolic and 95
diastolic (mmHg), averaged across four assessments on at least two separate days) or
serious ECG abnormalities (i.e. evidence of ischemia or myocardial infarction)28,41.
Participants taking the following medications on a chronic basis (greater than 30 days)
will be excluded from the study due the potential of these medications to interact with
psilocybin: tricyclic antidepressants, lithium, serotonin reuptake inhibitors, monoamine
oxidase inhibitors, haloperidol.
Thorough psychiatric interviews using the Structured Clinical Interview-5,
Alcohol Revised (SCID-5-AR) assessment will be conducted to identify and exclude
individuals with contraindicated psychological disorders (see Appendix C). This
psychiatric screening criteria is important for minimizing the chance (admittedly, already
low) of precipitating a longer-term psychotic, or adverse emotional or behavioral reaction
by hallucinogen administration.28,41 It will also enable us to decrease the chance that
symptoms from such disorders are inadvertently misattributed to the action of psilocybin
or ketamine. Individuals with other medical conditions that will preclude safe
participation in this study will be also be excluded (see Appendix C).
In order to minimize the potential for confounding, participants with a history of
cocaine, psychostimulant, opioid or cannabis dependence within the previous 12 months
will be excluded, as well as those participating in any formal treatment for alcohol
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dependence (12-step meetings are not considered treatment). Participants must have a
desire to stop or decrease their drinking, and at least two heavy drinking days (HDD)
within the previous 30 days.
2.4.4 Intervention
Pharmacological intervention:
The two leading candidates for application in the treatment of addiction are LSD
and psilocybin, as supported by the evidence presented here19. While LSD has the
advantage of an extensive body of literature on alcoholism treatment trials from the
1950s-1970s, psilocybin, has other advantages. Among them, psilocybin has a shorter
duration of action (four to six hours) compared to LSD (eight to twelve hours), making it
more amenable than LSD to administer outpatient. Additionally, it has been found to be
more strongly visual, less emotionally intense, more euphoric, and with fewer panic
reactions and less chance of paranoia than LSD30. These properties, together with the
evidence favoring psilocybin for the treatment of a variety of mental health disorders
have led us to choose psilocybin as the intervention in this proposed study.
Psilocybin dose:
In keeping with the psychedelic treatment model (vs. the psycholytic treatment
model; see “Psychosocial Intervention” section below for further information), we will
use a single high dose of psilocybin (0.3 mg/kg) in conjunction with several treatment
sessions. In completed clinical trials studying oral psilocybin, doses have ranged from
0.045 mg/kg (very low dose) to 0.428 mg/kg (very high dose), all of which were reported
to be safe and without serious adverse events. In Bogenschutz’s open-label trial on
psilocybin for AUD, participants received 0.3 mg/kg during the first session, and 0.4
mg/kg during the second session. In his follow-up RCT, doses will range from 25 mg/70
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kg to 40 mg/70 kg. In the study on tobacco dependence, oral psilocybin was administered
at a low dose (20 mg/70 kg) and a high dose (30 mg/70 kg) with an option for a third
dose (low or high). Based on these trials, we will administer 30 mg/70 kg of psilocybin in
a single session. Additional support for using this high dose comes from the literature,
which consistently demonstrates that higher doses of psilocybin lead to better
outcomes.19,28,34,37 Since all participants in this study will only be getting one dose of
psilocybin, it makes sense to maximize the possibility for therapeutic efficacy. While a
higher dose does increase the risk of adverse events, these events are typically nonserious and transient, resolving by the end of the dosing day. Furthermore, common
adverse events such as fear and anxiety respond well to reassurance and have not required
pharmacological intervention in previous studies.28
Ketamine dose:
Ketamine will be administered at a subanesthetic dose of 0.5 mg/kg during a 40minute IV infusion in order to blind participants, care providers, and outcome assessors
to the experimental treatment. This will be the first clinical trial with psilocybin to use
ketamine as an active placebo. This dose was chosen due to evidence from previous
experimental trials that it reliably exerted broad influences on consciousness and
perception.42,43 These effects typically emerge within 10 minutes of the start of the
infusion, and subside within 40 minutes of treatment termination, similar to the time
course of psilocybin’s effects. (Note, little to no psychoactive effects were observed at
the dose of 0.1 mg/kg).
While ketamine has been administered orally in certain clinical contexts, there is
far less research on the safety and pharmacodynamic effects of orally administered
ketamine compared to IV-administered ketamine82. Thus, we will have to employ a
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double dummy design in order to disguise the ketamine treatment from the experimental
session with psilocybin.
While the potential for ketamine to confound results cannot be excluded,
particularly given previous pilot work conducted in Russia in the 1990s that administered
ketamine in conjunction with psychotherapy for the treatment of AUD, we do not
anticipate this.83 This previous work had serious methodological flaws preventing any
significance conclusions on potential efficacy to be drawn. Furthermore, a more recent
double-blind treatment trial investigating the therapeutic potential of NMDA receptor
antagonists for AUD found that memantine did not have any significant effects on
reducing drinking behavior in alcohol-dependent patients.84
Psychosocial intervention:
There are two treatment models which have consistently been used throughout
clinical trials of psychedelic-assisted psychotherapy, and which have their origins in early
research with LSD therapy for alcoholism in the 1950s57. The two models, termed
psychedelic and psycholytic therapy, are based on different theoretical frameworks.
Psychedelic therapy involves high doses of a psychedelic (typically LSD, 200-800 g)
administered once or on a few occasions, with the goal of inducing a “peak-psychedelic,”
or mystical, experience.19,57. In contrast, in the psycholytic model, low to moderate doses
of hallucinogens (i.e. LSD 50-100 g or psilocybin 10-15 mg) are administered on
multiple occasions over months to years. The psycholytic treatment model incorporates
psychedelics into traditional psychoanalytic therapy, in order to accelerate the
therapeutic process.26 The psychedelic model has been used across various populations
including severe alcoholics, narcotic addicts, and individuals with existential anxiety
related to cancer-diagnoses and depression, with reported success.57,85-87 Most of the
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studies within the addiction treatment field (both early and recent) have used the
psychedelic model, including the two open-label trials on psilocybin-assisted
psychotherapy for AUD and tobacco dependence. Thus, the psychedelic treatment model
will be used in this study.
In keeping with the behavioral intervention used in Bogenschutz’s trials on
psilocybin for AUD, the psychosocial intervention utilized in this study will be MET.
While alternative approaches could be used, such as CBT or TSF, the key elements
believed to be driving change through hallucinogenic-assisted therapy are also central
targets of MET (i.e. motivation), thus when paired, they can work synergistically to affect
change. MET will be delivered using a structured approach that incorporates the
principles of motivational interviewing established in the Motivational Enhancement
Therapy Manual.88
2.5 Sample Size
The within group effect size was approximated from Bogenschutz’s pilot study on
psilocybin for AUD. In this study it was found that PHDD decreased during the fourweek period following psilocybin administration relative to the baseline by a mean
difference (SD) of 26.0 (22.4), 95% CI 8.7-43.2, p = 0.008. Based on this data, we
estimated a slightly more conservative difference of effect between psilocybin and
ketamine of d = 1.0. Due to an absence of data on the level of outcome in the ketamine
group, we estimated the effect of ketamine to be half the magnitude of the effect of
psilocybin (d = 0.5). This calculation yielded a sample size of 57.
2.6 Conclusion
New treatments are needed for AUD, and this new era of psychedelic research has
produced significant evidence for the promise of psilocybin-assisted therapy as a novel
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treatment option for AUD. This proposed study will aim to help fill the gaps in current
research. It is our hope that our results will provide further evidence for the therapeutic
role of psilocybin in addiction and that our study design may serve as a model for future
RCTs with psychedelics.
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Chapter 3 – Study Methods
3.1 Study Design
This study will be a 10-week randomized, double-blind, active-placebo-controlled
crossover trial to evaluate the effect of psilocybin-assisted treatment on drinking
outcomes relative to a ketamine control. A double-dummy design will be employed in
order to disguise psilocybin from ketamine (see Figure 1). Participants will be randomly
assigned to two separate dosing sequences: (1) psilocybin and ketamine placebo,
followed by ketamine and psilocybin placebo or, (2) ketamine and psilocybin placebo,
followed by psilocybin and ketamine placebo. The drug administration sessions will
occur within the context of 12 psychosocial sessions.

Figure 1: Intervention Design

3.2 Study Population and Sampling
The study population will include English-speaking adults, aged 25-65 with a
diagnosis of alcohol use disorder (in accordance with DSM-V criteria). Resources from
the Yale Center for the Translational Neuroscience of Alcoholism (CTNA), the VA
Alcohol Research Center (ARC), the Connecticut Mental Health Center (CMHC), and
the Alcoholism Treatment Center at Yale will be utilized for support in enrolling
subjects; clinicians at these sites will be informed of this study and asked to refer eligible
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and interested patients. Convenience sampling will be used to include heavy drinkers
who are motivated to seek help.
Participants will also be recruited from the general population using advertising
and recruitment media (i.e. Craigslist, Google, Twitter, Facebook, cable TV, and print
advertising and flyers). Advertisements will be designed to target heavy drinkers at
places and times they are expected likely to consider getting help for their drinking (i.e.
late-night TV ads, early morning radio and TV ads, and print advertising in heavily
trafficked urban areas).
For those individuals interested in participating who have provided verbal
consent, a pre-screen phone interview will be given to determine initial eligibility. Those
who pass this screening will be scheduled for an in-person screening visit at the
Alcoholism Treatment Center at Yale, where a trained research staff member will
administer the SCID-5-RV to provide a diagnosis of AUD1. Eligible subjects must meet
the inclusion and exclusion criteria outlined below in order to be invited. Once invited, all
participants will be randomly assigned to a treatment sequence.
3.3 Eligibility
Eligibility will be determined through assessment of the patient by a clinician, or
other trained study personnel. The subject’s clinical and medical information will be
reviewed by the research staff for any contraindications to research participation. The
inclusion and exclusion criteria will be used as a guide for eligibility. See Appendix C for
full inclusion/exclusion criteria.
In preparation of drug administration sessions participants must agree to: (1) Ingest
only alcohol-free liquids after 24:00 (midnight) the evening before the drug
administration session, and refrain the day of and the day after each drug administration
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session. (2) Refrain from the use of any psychoactive drug, with the exception of caffeine
or nicotine, within 24 hours of each drug administration session (3) Not use caffeine or
nicotine for two hours before and six hours after ingesting the drug, or until therapists
deem it safe to do so.
3.4 Subject Protection and Confidentiality
Prior to recruitment, we will attain Institutional Review Board (IRB) approval
through the Integrated Research Enterprise Solution-IRB submission system. All
necessary accompanying documents will be accessed through this system and submitted
along with the protocol application (see Appendices D-F). Study goals, timeline,
procedures, confidentiality practices, and all potential risks, discomforts, and benefits of
participation will be clearly outlined. Once IRB approval is obtained, a separate
Investigational New Drug (IND) application will be submitted.
Protection of participants’ research data will be compliant with Yale University
Procedure 400 PR.1 and the Health Insurance Portability and Accountability Act
(HIPAA). All identifiable research data, including recruitment and screening information
and code keys will be stored on a database located on a secure Yale-ITS network. Access
to the database will be password protected.
All subjects considered for participation in this study will be given an informed
consent and a thorough explanation of the study. All consents will be appropriately
documented. Risks to participants will be minimized. Selection of participants will be
equitable, and will not inappropriately exclude based on gender, race, age or other
criteria. We will not specifically recruit for a category of subjects that require special
safeguards (i.e. children, non-English speaking, prisoners, pregnant women). Subjects
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who are females of childbearing potential will require the following additional
safeguards/considerations upon their enrollment in the study (see Appendix C).
3.5 Study Variables and Measures
The intervention will be synthetic psilocybin (0.3 mg/kg) and its control will be
an inert capsule. Both pills will be delivered by a blinded pharmacist from the Yale
Investigational Pharmacy and swallowed with 100 ml. of water. The active control will
be intravenous ketamine 0.5 mg/kg and its control will be intravenous saline 0.9%, both
of which will be infused over 40 minutes by an anesthesiologist from Yale who will be
blinded.
The primary outcome (dependent variable) will be mean percent heavy drinking
days in each treatment arm, which will be measured with the TLFB method (a calendarbased form in which people provide retrospective estimates of their daily drinking over a
designated time period) at baseline, weeks two, six and 10. Heavy drinking days will be
defined as days during which participants consume five or more standard drinks (14 g of
alcohol) if male, or four or more standard drinks if female.
Several secondary outcomes will be measured. Motivation to change drinking
behavior (assessed with SOCRATES 8A; see Appendix G), self-efficacy (assessed with
the AASE; see Appendix H), and craving (assessed with PACS; see Appendix I) will be
measured at baseline, one day prior to dosing sessions, and one day after dosing sessions.
The acute subjective drug experience (assessed with the APZ Questionnaire) and the
mystical experience (assessed with the Mysticism Scale) will be collected seven hours
following dosing sessions. The APZ is a 72-item yes/no questionnaire and data will be
expressed as a percentage of maximum possible score. The mystical experience (assessed
with the MEQ 30) will be measured seven hours following drug administration at weeks
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two and six. The MEQ 30 will generate a total score, as well as four empirically derived
factors: mystical; positive mood; transcendence of time and space; and ineffability. The
monitor ratings (assessed with the MSRF) will be collected during the first six hours
following drug administration at weeks two and six. The MSRF will involve scoring
several dimensions of the participant’s mood or behavior, which will be rated on a 5point scale from 0 to 4 and expressed as peak scores. Data will be the mean of the two
monitor ratings at each time point.
Safety assessments will include: adverse events (collected on an adverse events
case report form) that will be monitored at every study visit. Cardiovascular measures
(systolic and diastolic blood pressure, heart rate) will be assessed during medication
sessions at the following time points: 30, 60, 90, 120, 180, 240, 300 160 minutes postdose administration.
Additional outcomes that will be collected at baseline include demographic and
clinical characteristics of study participants as follows: sex (male, female), age (mean
(SD)), race (White, Black, Hispanic, Asian, Other), highest level of education (high
school or less, some college, college, graduate/professional degree), religious/spiritual
beliefs (atheist/agnostic, Jewish, Catholic, Christian, other faith/tradition), mean duration
of alcohol dependence (in years), current tobacco use (yes/no), current marijuana use
(yes/no), previous alcohol treatment (yes/no; if yes, indicate).
Alcohol withdrawal will be assessed with CIWA-Ar, (reported as a score from 070, where ≥ 10 is indicative of alcohol withdrawal) at baseline and each drug
administration session. Urine pregnancy tests (UPT) for women of childbearing potential
will be collected at baseline and prior to each drug administration session. Breath Alcohol
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Concentration (BAC) and Urine toxicology screens will be measured at baseline and
every subsequent visit in order to ensure safety of treatment and validity of assessments.
See Figure 2 for an outline of data collection timepoints.
3.6 Methodology Considerations
At the medical screening visit, subjects will undergo a complete history and
physical examination and the following tests will be performed: ECG, liver function tests,
complete blood count, blood chemistries, urinalysis, serum pregnancy test, and body
mass index. Based on this data, subjects eligible for participation will be enrolled into the
study. Within two weeks of this screening, the first visit will take place. At this visit
subjects will meet with the study team including the therapists who will lead the MET
sessions and drug administration sessions. They will complete all baseline assessments
and be provided with a calendar of the study visits. Someone from the study team will
also orient them to the room where the drug administration sessions will take place, and
participants will be given an opportunity to address and questions or concerns they have.
After the baseline visit, participants will have four separate visits scheduled over a twoweek period – the first two visits will be MET sessions and the subsequent two will be
preparation sessions. At week two the first drug administration session will occur. A
four-week washout period will follow. During this period there will be a debriefing
session (the day after the drug session), two MET sessions at weeks three and four,
respectively, and a preparation session at week six the day prior to the second drug
administration session. Following the second drug administration session another
debriefing session will follow the next day, and then MET sessions will occur at weeks
seven, eight, and nine. (See Appendix J).
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The following resources will be used to develop and standardize the content for
the drug administration sessions and psychosocial intervention: (1) Project MATCH
Motivational Enhancement Therapy Manual (2) Human Hallucinogen Research:
Guidelines for Safety (3) Supplementary Materials from Bogenschutz’s Pilot Study and
RCT.2-6 A brief summary of what this will entail will follow.
3.6.1 Drug Administration Sessions
No more than one patient will be in a drug administration session on any given
day. Patients will arrive at the research facility in the morning (8:00-9:00 am) and
complete all necessary interim assessments. They will be taken to the dosing room where
they will be invited to relax on a bed in a supine or reclined position with eyeshades
while music is played through high-quality stereo speakers and earphones. The two
session monitors will sit on either side of the bed and will be present for the duration of
the session. Dosing will take place at approximately 10:30 am. Additional measurements
will be collected as necessary throughout the sessions, as stipulated in Section 3.6.
Tranquilizing medications (oral lorazepam and risperidone) will be on hand for
administration if necessary. Monitors will adopt a non-directive, supportive approach,
allowing the patient to experience a mostly uninterrupted inner “journey”. Upon the
session’s completion, patients will be picked up from the facility by a close friend or
relative who will bring them home and stay overnight with them.
3.6.2 Psychosocial Intervention
The psychosocial intervention will comprise a total of 12 sessions: seven MET
sessions, three preparation sessions and two debriefing sessions. The psychosocial
intervention will be delivered by a team of two therapists (session monitors) who will be
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present at every session, including the two drug administration sessions. One of the
therapists will perform the MET sessions, while the other will be responsible for
preparation before, support during, and debriefing after the drug administration sessions.
Therapy sessions will be audio-recorded and coded using the Motivational Interviewing
Treatment Integrity coding system by a rater trained to reliability.7
The goal of the first preparation sessions will be to conduct a detailed life review,
including information about the participant’s history, current situation, personality,
relationships, goals, etc., and to facilitate the development of rapport between the
participants and the therapists. The second preparatory session will include a review of
motivation and expectations for the study, detailed information about the physiological
and psychological effects of the drugs, and advice on how to deal with potential
dysphoric reactions to the drugs. The participant will be introduced to the aspects of the
dosing sessions and oriented to the room in which the session will take place. At all
preparatory sessions, the participant will be given the opportunity to address questions,
concerns, hopes, and fears related to the drug sessions.
De-briefing sessions will occur the day after each dosing session to allow the
participant to reflect on his experience during the dosing session. Open-ended
questioning techniques will be used to encourage the participant to discuss his experience
freely. Motivational interviewing techniques will be used to discuss how the session has
affected the participant’s relationship to alcohol and desire to change drinking behavior.
3.6.3 Blinding of Intervention
Double-blind randomization will be maintained by the Yale New Haven Hospital
(YNHH) Investigational Pharmacy, with joint-assistance from the CTNA. Psilocybin and
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its placebo will be prepared in identical opaque 0 gelatin capsules. The ketamine and
saline solutions will be supplied in identical 50-ml syringes containing either 0.9% saline
or ketamine with the additional volume of saline to total 50 ml. Participants, study
therapists, investigators, and outcome assessors will be blinded to the drug administration
conditions. At the end of each dosing session, the session monitors will record their
guesses as to whether the participants received psilocybin or ketamine. Participants will
not be asked to record their guesses as to which drug they receive on dosing session days.
3.6.4 Blinding of Outcome
Trained research staff will administer the TLFB to collect drinking data on every
participant. Session monitors will be blinded to the data until the end of the experimental
period at week 10.
3.6.5 Assignment of Intervention
Participants will be equally randomized to the two different dosing sequences via
a random-numbers chart. Randomization will not stratify for any demographic or clinical
characteristics. The randomization list will be kept with other study documents in a
secure location, available only to administrative staff. Upon entry of a new participant to
the trial, administrative staff will consult the allocation sequence and provide this
information unblinded to Yale pharmacy staff who will prepare the drugs. The
pharmacist who delivers the medication and the anesthesiologist to administer the
infusions will be blinded to the treatments.
3.6.6 Adherence
Incentives such as monetary compensation or vouchers will not be used in this
study. It is our hope that in selecting only individuals with a motivation to change their
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problematic drinking behaviors that participants will remain in the study until its
completion. The relatively short length of the study period (10 weeks) will hopefully
facilitate participant adherence. Nevertheless, some degree of dropout is nearly
inevitable, so we have accounted for dropout in our sample size calculation.
3.6.7 Monitoring of Adverse Events:
In order to monitor for any adverse events (AE) vital signs will be obtained at
each visit and at multiple timepoints throughout the drug sessions (see Section 3.6). Any
adverse events that do occur will be collected on an AE case report form at the end of the
session.
3.7 Data collection
Data for the primary outcome, mean PHDD, will be collected with the TLFB
method by a trained member of the study team at Baseline (data for previous 90 days);
week 2 (data for previous two weeks); week 6 (data for previous 4 weeks); and week 10
(data for previous 4 weeks). A trained study staff member will administer all additional
questionnaires and assessments. The below figure outlines the specific timepoints of data
collection.
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Figure 2: Data collection schedule for outcome measures and assessments

3.8 Sample Size Calculation
We used a t-test calculator to calculate sample size. Assuming a confidence level
of 1%, an effect size of d = 1.0, and a standard deviation of 22.4 to test a two-sided
hypothesis for a power of 80% and 10% dropout, we determined that we will need 57
subjects. We corrected the assumption for the confidence level due to the multiple
comparisons that would be tested in a crossover design.
3.9 Analysis
Descriptive statistics (means and proportions) will be used to describe the
baseline demographic and clinical characteristics of the study sample. Simple inferential
statistics will be used to compare the characteristics between the two dose-sequence
groups at baseline. T-tests will be used to compare continuous variables, and chi-square
tests will be used to compare categorical variables.
Between and within-group comparisons will be made for the primary outcome
and all secondary outcomes (motivation, self-efficacy, craving, mystical experience, and
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acute subjective effects). For the primary outcome of mean PHDD, the between-group
analysis will test the effect of the active intervention (i.e. the difference in mean PHDD
post-psilocybin in Arm 1 vs. the mean PHDD post-ketamine in Arm 2), and the withingroup analysis will test the effect of order. To test for these comparisons we will first test
the data for skewedness with the Kolmogorov-Smirnov and Shapiro-Wilk tests. If the
data are not skewed, within-group changes will be analyzed with a paired t-test and
between-group comparisons will be analyzed with an unpaired t-test. Additionally, mean
changes in PHDD and all secondary measures at all timepoints will be analyzed using
repeated measure ANOVA. If the data are skewed, the Wilxocon signed-rank test will be
used in place of the paired t-test and the non-parametric ANOVA-type statistic will be
used in place of the repeated measures ANOVA.8
3.10 Timeline and Resources
Resources from the CTNA, ARC, CMHC, Psychotherapy Development Research
Center, and the Alcoholism Treatment Center at Yale will be utilized for this study. They
will provide a trained clinician to administer the clinical diagnostic interview and medical
screening, and trained staff to monitor subject recruitment, generate the randomization
list, oversee self-reports and clinician-administered reports, and perform data analyses.
The YNHH Investigational Pharmacy will prepare the experimental drugs, and a YNHH
anesthesiologist will administer the intravenous solutions.
The recruitment period will last 12 months. Participants will be enrolled until the
target sample size of 56 individuals has been met. Upon enrollment, each participant will
be randomized to one of the two treatment sequences. Participants will not need to wait
until the target sample size is reached to achieve treatment since each participant will act
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as his/her own control. The treatment period will last a total of ten weeks. The entire
study period from recruitment to last follow-up is estimated to last 24 months.
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Chapter 4 – Conclusion
4.1 Strengths and Limitations
There are multiple converging but preliminary lines of evidence that heighten our
interest in testing psilocybin for AUD. In the last couple of decades researchers have built
upon the foundational work of their predecessors with enhanced study designs that
incorporate methods such as randomization, blinding, and a control-arm. Our study will
be the second to examine, in a randomized, placebo-controlled, double-blind fashion, the
efficacy of psilocybin on drinking outcomes in individuals with AUD. It will be a
necessary step to advance to the next phase of clinical research: Phase 3 trials.
One significant advantage of our study will be the use of ketamine as an active
control for psilocybin. This sets our study apart from previous psilocybin (and other
psychedelic) trials by incorporating another hallucinogen as the control condition. We
expect that this will preserve the blind and in turn minimize expectancy bias and enhance
validity. Despite evidence laid out in previous sections to the contrary, it is possible that
ketamine will have a positive effect on drinking outcomes, which could confound our
results. To address this, we have performed our sample size calculation accordingly, and
estimated the effect of ketamine to be half the magnitude of the effect of psilocybin.
Given the consistently large effect sizes detected for psilocybin in previous studies, we
still expect to detect a statistically significant difference in effect between psilocybin and
ketamine.
Some advantages of this proposed study distinguish it from Bogenschutz’s RCT.
First, the decision to include only hallucinogen-naïve individuals will help minimize
expectancy bias on the part of participants, who will not necessarily be able to distinguish
between the psychedelic drug effects due to lack of previous experience. Additionally,
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this will prevent selection bias by avoiding recruiting individuals who previously had
positive experiences with hallucinogens. The incorporation of a crossover design will
reduce between-patient variation since subjects will act as their own controls, and will
also allow for a smaller sample size, which will conserve study resources. A limitation of
the crossover design is that it may lead to carryover and period effects. While we cannot
be certain that the designated four-week washout period will be adequate, previous
evidence supports that this length of time will be sufficient for any remaining acute drug
effects to dissipate. We will further address these potential weaknesses by performing
between- and within-group statistical analyses of the data.
Additional limitations of this study include those inherent to psychedelic research
in general, which were mentioned in Chapter 2. While these challenges are formidable,
current research provides hope that they are surmountable.
4.2 Clinical and Public Health Significance
The potential advantages of a targeted intervention with psilocybin-assisted
therapy for the treatment of AUD are numerous. Despite significant progress in
alcoholism research over the past several decades, AUD remains a significant global
health burden, in need of alternative treatment options with greater efficacy in a broader
range of individuals.1,2 Current research indicates that psilocybin-assisted psychotherapy
may be the answer. If this therapy were to be approved, it would offer a cheaper, faster
alternative to current treatments, making it more accessible to a wider population.
Adherence would be less of a concern: instead of chronic daily pills (and their associated
costs and adverse effects), this therapy (if shown to be efficacious) would offer the
promise of long-term beneficial effects from just a single drug-administration session.
Additionally, unlike any single treatment today, this therapy addresses multiple domains
3

of addictive behavior, which the NIAAA has identified as necessary targets of future
alcoholism research (i.e. craving, self-efficacy, motivation).3,4 Such an integrative
approach could potentially treat a greater spectrum of the disease.
In order to prove the clinical efficacy of these drugs, additional Phase 2 placebocontrolled, double-blind, randomized controlled trials are needed to further demonstrate
feasibility safety and efficacy.
Bogenschutz predicts that “the therapeutic use of psychedelics in the treatment of
addiction … will continue to increase in coming years, possibly leading to approved
clinical uses for these medications.”5 While there is still a long road ahead before
psilocybin potentially becomes an FDA-approved treatment of addiction, the very recent
approval of esketamine (a ketamine derivative) for treatment-resistant depression
indicates that, perhaps, Bogenschutz’s predictions are not as far off as once thought.
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APPENDICES
Appendix A: Concept Table
Concept

Keyword
s/
MeSH
Terms

Related
Terms

Psilocybin /
Psychedelic-Assisted
Therapy
Psilocybin,
psilocybin/therapeutic
use,
psilocybin/administration
and dosage,
psilocybin/history,
Psilocybin/pharmacokine
tics,
Psilocybin/pharmacology

Ketamine /
Psychedelic-Assisted
therapy
Ketamine/therapeutic
use,
ketamine/administration
and dosage,
ketamine/pharmacokinet
ics,
ketamine/pharmacology

Alcohol Use
disorder

Hallucinogen*, psi,
psychedelic, indole
alkaloid, tryptamine*,
entheogen, psychotropic,
serotonergic, psychedelic,
5-HT2A receptors
agonist, mushroom,
mental disorders/drug
therapy,
psychotherapy, therapy,
behavioral intervention,
cognitive behavioral
therapy, motivational
interviewing,
motivational
enhancement therapy,
MET, CBT

Ketamine
hydrochloride,
esketamine, calypso,
kalipsol, ketanest,
ketaset, ketalar, (-)Ketamine, S-ketamine,
L-ketamine, ketaved
psychotherapy, therapy,
behavioral intervention,
cognitive behavioral
therapy, motivational
interviewing,
motivational
enhancement therapy,
MET, CBT

Addiction, AUD,
alcohol
dependence,
alcohol addiction,
heavy drinking,
chronic alcoholic,
problematic
drinking, alcohol
abuse, substance
use, substance
abuse, substance
use disorder,
addiction
treatment, chronic
alcohol
intoxication
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Alcoholism,
alcoholism/drug
therapy,
alcoholism/prevent
ion and control,
lcoholism/therapy

Appendix B: Sample size calculator

*Note: we calculated sample size for a within-group comparison, yielding N = 52. After
accounting for a 10% dropout the final sample size became N = 57 subjects.
Source: https://clincalc.com/Stats/SampleSize.aspx?example
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Appendix C: Table of inclusion and exclusion criteria
Inclusion Criteria
➢ Desire to stop or decrease their
drinking
➢ Have at least two heavy drinking days
in the past 30 days
➢ Not participating in any formal
treatment for alcohol dependence (12step meetings are not considered
treatment)
➢ English speaking- able to understand
the process of consent and the risks
and benefits associated with the
study, and able to provide voluntary
informed consent
➢ Must sign a medical release for the
investigators to communicate directly
with their therapist and doctors to
confirm a medication and/or
medication history
➢ Are willing to be driven home after
the drug administration sessions by a
driver arranged by the subject who
will also stay overnight with the
subject
➢ Must provide a contact (relative,
spouse, close friend, or other
caregiver) who is willing and able to
be reached by the Clinical
Investigators in the event of a
participant becoming suicidal.
➢ If female of childbearing potential,
are willing to use approved form of
contraception from screening until
after the psilocybin administration
sessions
➢ Able to provide adequate locator
information
➢ No prior history of hallucinogen use

Exclusion Criteria
➢ The following medical conditions:
seizure disorder, significantly impaired
liver function, coronary artery disease,
heart failure, uncontrolled
hypertension (>165/95), history of
cerebrovascular accident, asthma,
hyperthyroidism, narrow-angle
glaucoma, stenosing peptic ulcer,
pyloroduodenal obstruction,
symptomatic prostatic hypertrophy,
bladder-neck obstruction.
➢ The following psychiatric conditions:
schizophrenia or other psychotic
disorders, bipolar I or II disorder,
current major depressive episode,
current post-traumatic stress disorder,
current suicidality or history of
medically serious suicide attempt
➢ Cognitive impairment (Folstein Mini
Mental State Exam score <26)
➢ Family history of schizophrenia,
schizoaffective disorder (first- or
second-degree relatives), or bipolar
disorder type 1 (first degree relatives)
➢ Cocaine, psychostimulant, opioid or
cannabis dependence (past 12 months)
➢ Current (past 30 days) or non-medical
use of cocaine, psychostimulants (i.e.
dextroamphetamine,
methamphetamine, methylphenidate,
ephedrine, phenylpropanolamine, and
other anorectics and decongestants) or
opioids.
➢ Significant alcohol withdrawal
(CIWA-Ar score >7. Patients
presenting at screening in withdrawal
may be referred for detoxification and
reassessed within 30 days)
➢ Serious ECG abnormalities (i.e.
evidence of ischemia or MI)
➢ Serious abnormalities of CBC or
chemistries
➢ Active legal problems with the
potential to result in incarceration
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➢ Pregnancy or lactation
➢ Need to take the following
medications: antidepressants,
antipsychotics, psychostimulants,
treatments for addictions, other
dopaminergic or serotonergic agents,
lithium, anticonvulsants)
➢ High risk of adverse emotional or
behavioral reaction based on
investigator’s clinical evaluation (i.e.
evidence of serious personality
disorder, antisocial behavior, serious
current stressors, lack of meaningful
social support)
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Appendix D: Informed consent form
CONSENT FOR PARTICIPATION IN A RESEARCH PROJECT
200 FR. 1 (2016-2)
YALE UNIVERSITY SCHOOL OF MEDICINE – YALE-NEW HAVEN HOSPITAL

Study Title: Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder: A DoubleBlind Randomized Control Trial
Principal Investigator: John Krystal, MD
You are invited to participate in a research study designed to look at whether
psychedelic-assisted treatment with psilocybin of alcohol use disorder (AUD) is clinically
useful. Specifically, this study aims to: (1) characterize the acute effects of psilocybin in
alcoholic patients (2) evaluate the effect of psilocybin treatment on drinking outcomes
relative to a ketamine control. You are being asked to participate because you have been
identified as someone who meets the eligibility requirements for our study.
In order to decide whether or not you wish to be a part of this research study you
should know enough about its risks and benefits to make an informed decision. This
consent form gives you detailed information about the research study, which a member of
the research team will discuss with you. This discussion should go over all aspects of this
research: its purpose, the procedures that will be performed, any risks of the procedures,
possible benefits and possible alternative treatments. Once you understand the study, you
will be asked if you wish to participate; if so, you will be asked to sign this form.
Description of Procedures
Guidelines:
➢ Psilocybin and ketamine are classified as hallucinogens due to their ability to
induce the following effects in humans: broad influences on consciousness and
perception, including dissociation, distortions in visual, auditory, or somatosensory
stimuli, or alterations in the perception of self or time, conceptual disorganization,
hallucinations.
➢ You will be randomly assigned to one of the two treatment sequences (both
sequences receive identical treatments, just in a different order – i.e. AB/BA or
BA/AB). The treatments you will receive will be both pharmacological and
psychosocial in nature.
➢ The pharmacological intervention will consist of two drug sessions. At each drug
session both a pill and an intravenous treatment will be administered; the
combination will always consist of an active treatment (moderate to high doses of
either psilocybin or ketamine) paired with an inactive one (a placebo pill or IV
saline solution); whichever combination you receive at the first session, you will
receive the alternate at the second session, so that by the end of the trial you will
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➢

➢

➢

➢
➢

➢

➢

have received both ketamine and psilocybin. The purpose of creating to dosing
sequences is to disguise which drug you will be getting at each session so as to
preserve the integrity of the experiment.
The psychosocial treatment will consist seven sessions of motivational
enhancement therapy, three preparation sessions, and two debriefing sessions.
Content of therapy, preparation, and debriefing sessions may vary according to
the participant’s needs; however, all sessions will follow the same standardized
guidelines. These additional treatment components have been standardized in
previous research, and are necessary components of psychedelic-assisted therapy
to ensure your safety throughout the trial and maximize potential beneficial
treatment effects. (See image below for outline of study visits). All study visits
will take place at the Alcohol Treatment Center at Yale
Motivational enhancement therapy (MET) is a common intervention for the
treatment of alcohol dependence. It consists of a patient-centered therapy that
aims to produce rapid internally-motivated changes by exploring and resolving
ambivalence towards behavior.
Preparation sessions will consist of a review of motivation and expectations for
the study, detailed information about the physiological and psychological effects
of the drugs, and advice on how to deal with potential dysphoric reactions to the
drugs. At your first dosing session you will be oriented to the room in which the
drug sessions will take place, shown the eye shades and headphones to be worn,
and played a sample of the music to be played.
Debriefing sessions will occur on the following each drug administration session
to allow you participant to reflect on his experience during the drug
administration session.
During study visits you will be asked to complete questionnaires about your
drinking behavior and aspects related to your drinking such as self-efficacy,
craving, and motivation. The data from these questionnaires will be used to help
us analyze the efficacy of the intervention.
Biological samples will be collected at an in-person screening visit in order to
determine study eligibility (i.e. ECG, liver function tests, complete blood count,
blood chemistries, urinalysis, and serum pregnancy test if female of child-bearing
potential). Alcohol withdrawal will be assessed at a baseline visit and both drug
administration sessions. Breath alcohol concentration will be collected at every
visit in order to ensure your safe participation in the study.
All data collected as part of this study will remain confidential; it will not be
included in your medical records nor will it be accessible to your medical
providers.

If you agree to participate in this study, you will be asked to attend all study visits
outlined above. See figure below for further clarification.
A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as
required by U.S. Law. This Web site will not include information that can identify you.
At most, the Web site will include a summary of the results. You can search this Web site
at any time.
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You will be told of any significant new findings that are developed during the course of
your participation in this study that may affect your willingness to continue to participate.
Figure 1: Timeline of study visits

Risks and Inconveniences
Guidelines:
➢ Ketamine and psilocybin have similar psychopharmacological effects. Lower
doses of these drugs may induce a mild state of euphoria that is similar to that
produced by a glass of wine, whereas higher subanesthetic doses (i.e. 0.5 mg/kg,
IV over 40 minutes) produce alterations in sensory perception, feelings of
unreality, and in some subjects mild psychosis. These drugs have also been found
to affect cognition (i.e. decrease mental sharpness, recall, and recognition) either
during or shortly following administration. At doses perception-altering doses,
these drugs may produce nausea and, in some cases, vomiting; this symptom may
be managed by pretreatment with odansetron. In healthy subjects, these drugs
typically produce a mild elevation in blood pressure and pulse rate that typically
does not require medical intervention. Repeated ketamine administration appears
to be safe when managed clinically. However, long-term heavy recreational use of
ketamine, which can reach daily levels of 100-times the therapeutic dose, may lead
to flashbacks, attentional, and other cognitive dysfunctions. Participation in this
study may involve risks that are currently not known.
➢ There is a federal law called the Genetic Information Nondiscrimination Act
(GINA) that, in general, makes it illegal for health insurance companies, group
health plans, and most employers, except those with fewer than 15 employees, to
discriminate against you based on your genetic information. However, it does not
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protect you against discrimination by companies that sell life insurance, disability
insurance, or long-term care insurance.
Contrast Risks and Procedures Statements.
Having an intravenous (IV) line placed is a very safe procedure. There is a slight
chance that multiple needle-sticks will be needed to make sure the IV is placed correctly.
You might feel a small amount of pain when the IV is placed but it does not last very
long. A bruise or a minor infection might develop where the IV is placed. A bruise will
go away by itself and it might help if you wrap a warm towel around your arm.
Infections can also be treated if necessary.
You should tell your principal investigator: (1) if you are pregnant or breast
feeding, (2) if you have a history of kidney disease, seizure, asthma, or allergic
respiratory disorders, and (3) if you have anemia or disease that affects red blood cells.
Benefits
Guidelines:
➢ There remains substantial room for the development of effective treatment
alternatives for AUD and classic hallucinogens, particularly psilocybin, have
shown promise in early studies. Recently completed proof-of-concept studies of
psilocybin in conjunction with psychotherapy for nicotine and alcohol dependence
demonstrated that the intervention led to substantial decreases in use of the target
substance. Your participation in this study will help us to further understand the
therapeutic role psilocybin for the treatment of AUD, with the possibility that in the
future this treatment could become an approved alternative for many patients
afflicted with this disease.
➢ The proposed psilocybin intervention as a treatment for AUD is still under
investigation and currently unproven, thus we cannot guarantee that you will
benefit from this treatment. However, MET is an established treatment for AUD
and it is reasonable to expect
Economic Considerations
Guidelines:
➢ You will be compensated for any costs involved in transporting to and from the
study center. According to the rules of the Internal Revenue Service (IRS),
payments that are made to you as a result of your participation in a study may be
considered taxable income.
➢ All costs associated with the medical screening visit (i.e. physical exam, laboratory
tests) and all treatment interventions (drug sessions and therapy visits) will be
covered by the study.
Treatment Alternatives/Alternatives
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Guidelines:
Current treatment options for AUD consist of pharmacological interventions, behavioral
therapy, and mutual support groups. The FDA has approved only three drugs for AUD:
Naltrexone, Acamprosate, and Disulfiram, and these medications display poor efficacy,
low adherence rates, or adverse effects at a population level.1 Empirically-validated
behavioral interventions include cognitive behavioral therapy, motivational interviewing,
and marital and family counseling. Mutual support treatment groups include Alcoholics
Anonymous and other 12-step programs.

Confidentiality
Guidelines:
Except as permitted by law, your health information will not be released in an identifiable
form outside of the Yale University research team. Examples of information that we are
legally required to disclose include abuse of a child or elderly person, or certain
reportable diseases. Note, however, that your records may be reviewed by those
responsible for the proper conduct of research such as the Yale University Human
Research Protection Program, Yale University Human Subjects Committee or
representatives of the U.S. Department of Health and Human Services. The information
about your health that will be collected in this study includes:
➢ Baseline medical information (i.e. relevant current or past medical conditions,
medication use, substance use)
➢ History of alcohol use disorder (i.e. date of first diagnosis, previous treatments
received)
➢ Baseline biological data (i.e. blood tests, ECG) as mentioned above
➢ Any personal material disclosed during therapy sessions
Information may be re-disclosed if the recipients are not required by law to protect the
privacy of the information. At the conclusion of this study, any identifying information
related to your research participation will be de-identified, rendering the data anonymous.
Authorized representatives of the Food and Drug Administration (FDA) and the
manufacturer of the drug being tested may need to review records of individual subjects.
As a result, they may see your name; but they are bound by rules of confidentiality not to
reveal your identity to others.
Guidelines:
If you are injured while on study, seek treatment and contact the study doctor as soon as
you are able.
Yale School of Medicine, Yale-New Haven Hospital, and the Connecticut Mental Health
Center do not provide funds for the treatment of research-related injury. If you are injured
as a result of your participation in this study, treatment will be provided. You or your
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insurance carrier will be expected to pay the costs of this treatment. No additional financial
compensation for injury or lost wages is available.
You do not give up any of your legal rights by signing this form.
Voluntary Participation and Withdrawal
Guidelines:
Participating in this study is voluntary. You are free to choose not to take part in this
study. Refusing to participate will involve no penalty or loss of benefits to which you
are otherwise entitled (such as your health care outside the study, the payment for your
health care, and your health care benefits). However, you will not be able to enroll in this
research study and will not receive study procedures as a study participant if you do not
allow use of your information as part of this study.
Withdrawing From the Study
If you do become a subject, you are free to stop and withdraw from this study at any time
during its course. To withdraw from the study, you can call a member of the research
team at any time and tell them that you no longer want to take part. This will cancel any
future appointments.
The researchers may withdraw you from participating in the research if necessary (i.e. if
you are no longer compliant with exclusion/inclusion criteria of this study, or if you
experience serious adverse side effects from the drug(s)). Withdrawing from the study will
involve no penalty or loss of benefits to which you are otherwise entitled. It will not harm
your relationship with your own doctors or with New Haven Hospital or the Connecticut
Mental Health Center. We would still, at your request, refer you to a clinic or doctor who
can offer you treatment.
When you withdraw from the study, no new health information identifying you will be
gathered after that date. Information that has already been gathered may still be used and
given to others until the end of the research study, as necessary to insure the integrity of
the study and/or study oversight.
Questions
We have used some technical terms in this form. Please feel free to ask about
anything you don't understand and to consider this research and the consent form carefully
– as long as you feel is necessary – before you make a decision.
Authorization
I have read (or someone has read to me) this form and have decided to participate in the
project described above. Its general purposes, the particulars of my involvement and
possible hazards and inconveniences have been explained to my satisfaction. My signature
also indicates that I have received a copy of this consent form.
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Name of Subject:_____________________________

Signature:___________________________________
Relationship:________________________________
Date:______________________________________

___________________________________________
Signature of Principal Investigator

___________________
Date

or
___________________________________________
Signature of Person Obtaining Consent

___________________
Date

If you have further questions about this project or if you have a research-related problem,
you may contact the Principal Investigator John Krystal, MD.
If, after you have signed this form you have any questions about your privacy rights,
please contact the Yale Privacy Officer at 203-432-5919. If you would like to talk with
someone other than the researchers to discuss problems, concerns, and questions you may
have concerning this research, or to discuss your rights as a research subject, you may
contact the Yale Human Investigation Committee at (203) 785-4688.
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Appendix E: Verbal consent form
Information Sheet
Verbal Consent for Participation in a Research Study
200 FR 9 (2017-2)
YALE UNIVERSITY SCHOOL OF MEDICINE – YALE-NEW HAVEN HOSPITAL
Study Title: Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder: A DoubleBlind Randomized Control Trial
Principal Investigator: John Krystal, MD
Introduction
You are being asked to join a research study. The following information will explain the
purpose of the study, what you will be asked to do, and the potential risks and benefits.
You should ask questions before deciding whether you wish to participate, or at any time
during the course of the study.
Purpose
The purpose of this study is to further clarify whether psilocybin-assisted treatment of
AUD is clinically useful. You are being asked to participate because you have been
identified as someone who meets the eligibility requirements for our study.
Procedures
If you choose to participate in the study, you will be asked to fully comply with the
procedures of our study, which are described as follows:
➢ You will be randomly assigned to one of the two treatment sequences (both
sequences receive identical treatments, just in a different order – i.e. AB/BA,
BA/AB)
➢ Treatment will consist of two blinded drug administration sessions, seven
sessions of motivational enhancement therapy, three preparation sessions, and
two debriefing sessions. Content of therapy, preparation, and debriefing sessions
may vary according to the participant’s needs, however, all sessions will follow
the same standardized guidelines
➢ Biological samples will be collected at an in-person screening visit in order to
determine study eligibility (i.e. ECG, liver function tests, complete blood count,
blood chemistries, urinalysis, and serum pregnancy test if female of child-bearing
potential). Alcohol withdrawal will be assessed at a baseline visit and both drug
administration sessions. Breath alcohol concentration will be collected at every
visit in order to ensure your safe participation in the study.
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➢ All data collected as part of this study will remain confidential; it will not be
included in your medical records nor will it be accessible to your medical
providers.
Possible Benefits
This research may or may not benefit you directly. However, knowledge gained from the
results may help us to better understand the efficacy of psychedelic-assisted therapy for
the treatment of alcohol use disorder.
Possible Risks
Your part in this research study consists solely of abiding to the protocol as specified
above. This study does require you to have treatments, including the administration of
drugs which are not currently approved for clinical use by the U.S. Food and Drug
Administration. The potential exists for anticipated and/or unanticipated adverse events,
serious or otherwise, to occur. Additionally, there is a slight risk regarding the
confidentiality of your participation in this study, if information about you becomes
known to persons outside this study. The researchers are required to keep your study
information confidential, however, so the risk of breach of confidentiality is very low.
Alternatives to Participation
Study staff will provide you will all information on alternative treatment options. Your
participation in this study is voluntary. You are free to choose not to take part in this
study at any time.
Privacy / Confidentiality
To protect your confidentiality, your name and other identifying information will not be
recorded on any study documents. We will only collect information that is needed for
research. Only the researchers involved in this study and those responsible for research
oversight will have access to the information you provide.
Research Authorization:
Except as permitted by law, your health information will not be released in an identifiable
form outside of the Yale University research team. Examples of information that we are
legally required to disclose include abuse of a child or elderly person, or certain
reportable diseases. Note, however, that your records may be reviewed by those
responsible for the proper conduct of research such as the Yale University Human
Research Protection Program, Yale University Human Subjects Committee [or
representatives of the U.S. Department of Health and Human Services or the name of
research sponsor if applicable). The information about your health that will be collected
in this study includes:
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➢ Baseline medical information (i.e. relevant current or past medical conditions,
medication use, substance use)
➢ History of alcohol use disorder (i.e. date of first diagnosis, previous treatments
received)
➢ Baseline biological data (i.e. blood tests, ECG) as mentioned above
➢ Any personal material disclosed during therapy sessions
Information may be re-disclosed if the recipients are not required by law to protect the
privacy of the information. At the conclusion of this study, any identifying information
related to your research participation will be de-identified, rendering the data anonymous.
By agreeing to participate in this study, you authorize the use and/or disclosure of the
information described above for this research study. The purpose for the uses and
disclosures you are authorizing is to ensure that the information relating to this research is
available to all parties who may need it for research purposes.
This authorization to use and disclose your health information collected during your
participation in this study will never expire.
Voluntary Participation
Participation in this study is completely voluntary. You are free to decline to participate,
to end participation at any time for any reason, or to refuse to answer any individual
question at any time. Refusing to participate will involve no penalty or loss of benefits
to which you are otherwise entitled (such as your health care outside the study, the
payment for your health care, and your health care benefits). By providing verbal
consent, you have not given up any of your legal rights.
Questions
You have heard the above description of the research study. You have been told of the
risks and benefits involved and, at this point, all of your questions regarding the study
have been answered.
If you have any further questions about this study, you may contact the investigator,
John Krystal, MD. If you would like to talk with someone other than the researchers to
discuss problems, concerns, and questions you may have concerning this research, or to
discuss your rights as a research subject, you may contact the Yale Human Investigation
Committee at (203) 785-4688.
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Appendix F: Data and safety monitoring plans form
Data and Safety Monitoring Plans (DSMP)
420 FR.1

Greater Than Minimal Risk DSMP
1. Personnel responsible for the safety review and its frequency:
The principal investigator will be responsible for monitoring the data, assuring protocol
compliance, and conducting the safety reviews at the specified frequency, which must be
conducted at a minimum of every 6 months (including when reapproval of the protocol is
sought). During the review process, the principal investigator (monitor) will evaluate
whether the study should continue unchanged, require modification/amendment, or close
to enrollment. Either the principal investigator, the IRB or Yale Data and Safety
Monitoring Committee (DSMC) have the authority to stop or suspend the study or
require modifications.
2. The risks associated with the current study are deemed greater than minimal for
the following reasons:
1. We do not view the risks associated with psilocybin and ketamine as minimal
risks.
2. Given the now established safety and validity of the current study drugs in our
prior work, we do not view the proposed studies as high risk.
Although we have assessed the proposed study as one of greater than minimal risk, the
potential exists for anticipated and/or unanticipated adverse events, serious or otherwise,
to occur since it is not possible to predict with certainty the absolute risk in any given
individual or in advance of first-hand experience with the proposed study methods.
Therefore, we provide a plan for monitoring the data and safety of the proposed study as
follows:
3. Attribution of Adverse Events:
Adverse events will be monitored for each subject participating in the study and
attributed to the study procedures / design by the principal investigator John Krystal,
MD., according to the following categories:
a.) Definite: Adverse event is clearly related to investigational procedures(s)/agent(s).
b.) Probable: Adverse event is likely related to investigational procedures(s)/agent(s).
c.) Possible: Adverse event may be related to investigational procedures(s)/agent(s).
d.) Unlikely: Adverse event is likely not to be related to the investigational
procedures(s)/agent(s).
e.) Unrelated: Adverse event is clearly not related to investigational
procedures(s)/agent(s).
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4. Plan for Grading Adverse Events:
The following scale will be used in grading the severity of adverse events noted during
the study:
1. Mild adverse event
2. Moderate adverse event
3. Severe
5. Plan for Determining Seriousness of Adverse Events:
Serious Adverse Events:
In addition to grading the adverse event, the PI will determine whether the adverse event
meets the criteria for a Serious Adverse Event (SAE). An adverse event is considered
serious if it results in any of the following outcomes:
1. Death;
2. A life-threatening experience in-patient hospitalization or prolongation of
existing hospitalization;
3. A persistent or significant disability or incapacity;
4. A congenital anomaly or birth defect; OR
5. Any other adverse event that, based upon appropriate medical judgment, may
jeopardize the subject’s health and may require medical or surgical intervention
to prevent one of the other outcomes listed in this definition.
An adverse event may be graded as severe but still not meet the criteria for a Serious
Adverse Event. Similarly, an adverse event may be graded as moderate but still meet the
criteria for an SAE. It is important for the PI to consider the grade of the event as well as
its “seriousness” when determining whether reporting to the IRB is necessary.
6. Plan for reporting UPIRSOs (including Adverse Events) to the IRB
The principal investigator will report the following types of events to the IRB:
Any incident, experience or outcome that meets ALL 3 of the following criteria:
1. Is unexpected (in terms of nature, specificity, severity, or frequency) given (a)
the research procedures described in the protocol-related documents, such as
the IRB-approved protocol and informed consent document and (b) the
characteristics of the subject population being studied; AND
2. Is related or possibly related to participation in the research (possibly related
means there is a reasonable possibility that the incident, experience, or
outcome may have been caused by the procedures involved in the research);
AND
3. Suggests that the research places subjects or others at greater risk of harm
(including physical, psychological, economic, legal, or social harm) than was
previously known or recognized.
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Unanticipated Problems Involving Risks to Subjects or Others (UPIRSOs) may be
medical or non-medical in nature, and include – but are not limited to – serious,
unexpected, and related adverse events and unanticipated adverse device effects.
Please note that adverse events are reportable to the IRB as UPIRSOs only if they
meet all 3 criteria listed above.
These UPIRSOs/SAEs will be reported to the IRB in accordance with IRB Policy 710,
using the appropriate forms found on the website. All related events involving risk but
not meeting the prompt reporting requirements described in IRB Policy 710 should be
reported to the IRB in summary form at the time of continuing review. If appropriate,
such summary may be a simple brief statement that events have occurred at the expected
frequency and level of severity as previously documented. In lieu of a summary of
external events, a current DSMB report can be submitted for research studies that are
subject to oversight by a DSMB (or other monitoring entity that is monitoring the study
on behalf of an industry sponsor).
7. Plan for reporting adverse events to co-investigators on the study, as appropriate
the protocol’s research monitor(s), e.g., industrial sponsor, Yale Cancer Center
Data and Safety Monitoring Committee (DSMC), Protocol Review Committee
(PRC), DSMBs, study sponsors, funding and regulatory agencies, and regulatory
and decision-making bodies.
For the current study, the following individuals, funding, and/or regulatory agencies will
be notified:
□ All Co-Investigators listed on the protocol.
□ Food and Drug Administration
□ Study Sponsor
The principal investigator John Krystal, MD., will conduct a review of all adverse events
upon completion of every study subject. The principal investigator will evaluate the
frequency and severity of the adverse events and determine if modifications to the
protocol or consent form are required.
Please note: For any study that may be considered high risk, the IRB will be more
focused on the safety requirements for the study and a DSMB will likely be required.
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Appendix G: Personal Drinking Questionnaire (SOCRATES-8A)
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Appendix H: Alcohol Abstinence Self-Efficacy Scale
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ID #: _________________________

Date: ___ ___ / ___ ___ / ___ ___ ___ ___

ALCOHOL ABSTINENCE SELF-EFFICACY (AASE)
NEGATIVE AFFECT
18 or 38.
16 or 36.
3 or 23.
14 or 34.
6 or 26.

When I am feeling angry inside
When I sense everything is going wrong for m e
When I am feeling depressed
When I feel like blowing up because of frustration
When I am very worried

SOCIAL/POSITIVE
15 or 35.
20 or 40.
4 or 24.
17 or 37.
8 or 28.

When I see others drinking at a bar or at a party
When I am excited or celebrating with others
When I am on vacation and want to relax
When people I used to drink with encourage me to drink
When I am being offered a drink in a social situation

PHYSICAL AND OTHER CONCERNS
2 or 22.
12 or 32.
5 or 25.
13 or 33.
9 or 29.

When I have a headache
When I am physically tired
When I am concerned about someone
When I am experiencing some physical pain or injury
When I dream about taking a drink

CRAVING AND URGES
1 or 21.
7 or 27.
11 or 31.
10 or 30.
19 or 39.

When I am in agony because of stopping or withdrawing from alcohol use
When I have the urge to try just one drink to see what happens
When I am feeling a physical need or craving for alcohol
When I want to test my willpower over drinking
When I experience an urge or impulse to take a drink that catches me unprepared

ADAI Sound Data Source—1/26/2007

{Project information}

http://adai.washington.edu/sounddatasource
Page 3
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Appendix I: Penn Alcohol Craving Scale (PACS)
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Appendix J: Proposed protocol timeline for study visits and assessments
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